Lyra Therapeutics Inc (NASDAQ: LYRA) on Tuesday, plunged -1.94% from the previous trading day, before settling in for the closing price of $0.19. Within the past 52 weeks, LYRA’s price has moved between $0.16 and $6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 58.51% over the past five years. The company achieved an average annual earnings per share of -6.83%. With a float of $54.79 million, this company’s outstanding shares have now reached $65.46 million.
Let’s look at the performance matrix of the company that is accounted for 88 employees. In terms of profitability, gross margin is -816.72%, operating margin of -6894.43%, and the pretax margin is -6632.36%.
Lyra Therapeutics Inc (LYRA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lyra Therapeutics Inc is 16.29%, while institutional ownership is 46.47%.
Lyra Therapeutics Inc (LYRA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -6.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.60% during the next five years compared to -21.63% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Lyra Therapeutics Inc (LYRA) is currently performing well based on its current performance indicators. A quick ratio of 3.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics Inc (NASDAQ: LYRA) saw its 5-day average volume 1.46 million, a negative change from its year-to-date volume of 1.7 million. As of the previous 9 days, the stock’s Stochastic %D was 8.98%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 10.74%, which indicates a significant decrease from 18.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.90% in the past 14 days, which was lower than the 93.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2244, while its 200-day Moving Average is $1.4035. Nevertheless, the first resistance level for the watch stands at $0.1895 in the near term. At $0.1971, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2067. If the price goes on to break the first support level at $0.1723, it is likely to go to the next support level at $0.1627. The third support level lies at $0.1551 if the price breaches the second support level.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
Market capitalization of the company is 11.91 million based on 65,458K outstanding shares. Right now, sales total 1,560 K and income totals -62,680 K. The company made 200 K in profit during its latest quarter, and -11,870 K in sales during its previous quarter.
